Of the 40 million people living with HIV globally, UNAIDS estimates 9.3 million were still not receiving treatment in 2023. Many of these people live in low- and middle-income countries. We are committed to enabling access to our medicines to benefit people affected by HIV, regardless of their income, location, status, age or gender.
Our access to medicines strategy considers the specific challenges faced in terms of epidemic burden and economic status.
The strategy includes all low-income, least-developed, middle income and Sub-Saharan African countries (developing countries) where the unmet need for anti-retroviral therapy (ART) is greatest.
By working together with our national partners, we are helping to drive greater access to treatments.
We are also encouraging a positive environment for the continued development of new treatments options and preventative approaches, to support PLHIV and those at risk of HIV infection.
Resolving the persistent problem of health disparities is the central focus of Achieving health equity: a roadmap to eliminating disparities, a report sponsored by ViiV Healthcare and conducted by Economist Impact.
We are playing a part in working towards the United Nations (UN) Sustainable Development Goal to end the HIV/AIDS epidemic by 2030 and achieve an HIV-free future.
Our partnership with the Fast-Track Cities initiative is testament of our ongoing support towards meeting UN’s HIV-free future goal.
YOU MAY ALSO BE INTERESTED IN:
The latest global statistics from UNAIDS, state that 1.7 million children are currently living with HIV and only half of those children with HIV have access to treatment, compared with 68% of adults.
ViiV Healthcare is working with thought leaders and influencers living with HIV from across the globe to challenge the perception of what living with HIV ‘looks like’.
One country that’s making headway in the fight against HIV is Botswana, where 360,000 people living with HIV (PLHIV) live. This is despite outstanding achievements in addressing gaps in HIV treatment and care in the country.
NP-GBL-HVX-COCO-240015 | October 2024
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
